Orchard Therapeutics Revenue 2017-2021 | ORTX

Orchard Therapeutics revenue from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Orchard Therapeutics Annual Revenue
(Millions of US $)
2020 $3
2019 $3
2018 $2
2017 $
2016 $
Orchard Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31
2020-09-30 $2
2020-06-30 $1
2020-03-31
2019-12-31 $1
2019-09-30 $2
2019-06-30
2019-03-31
2018-12-31 $1
2018-09-30 $1
2018-06-30
2018-03-31
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.273B $0.003B
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00